01/26/23 8:30 AMNasdaq : VERU conferencesearningsVeru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9,RHEA-AIneutral
01/10/23 8:30 AMNasdaq : VERU managementVeru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory BoardVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious diseaseRHEA-AIneutral
12/05/22 6:30 AMNasdaq : VERU earningsVeru Reports Fiscal 2022 Fourth Quarter and Full Year Financial ResultsU.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states Sabizabulin also under review for potential emergency authorization byRHEA-AIneutral
11/28/22 8:30 AMNasdaq : VERU conferencesearningsVeru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2022,RHEA-AIneutral
11/09/22 8:55 PMNasdaq : VERU covid-19Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today’s meeting of the U.S. Food and Drug Administration’s (FDA)RHEA-AInegative
10/24/22 8:30 AMNasdaq : VERU covid-19Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced data from the late-breaker oral presentation of the Phase 3 trial ofRHEA-AIneutral
10/13/22 8:30 AMNasdaq : VERU conferencescovid-19Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate toRHEA-AIneutral
10/04/22 4:30 PMNasdaq : VERU Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards toRHEA-AIneutral
09/21/22 8:30 AMNasdaq : VERU conferencesVeru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate inRHEA-AIneutral
09/19/22 12:15 PMNasdaq : VERU covid-19Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for theRHEA-AIneutral